Table 3.

Clinical characteristics of patients undergoing RPFNA

A. Patient characteristics for RPFNA
Women enrolled in study38
Bilateral RPFNA28
Unilateral RPFNA10
RPFNA samples collected66
No. RPFNAs with insufficient epithelial cell count10
No. RPFNAs submitted for analysis56
n = 38 (%)
Average age and range (y)46 (29-64)
Race
    Caucasian33 (87)
    African American5 (13)
Menopausal status
    Postmenopausal18 (47)
    Premenopausal/Perimenopausal20 (53)
Hormone replacement use
    Current2 (5)
    Ever use9 (24)
    Never use27 (71)
Antiestrogen therapy (at the time of RPFNA)
    Tamoxifen2 (5)
    Raloxifene1 (3)
    Aromatase inhibitor2 (5)
Family history of breast cancer17 (45)
Prior abnormal biopsies
    LCIS1 (3)
    DCIS5 (13)
    ADH10 (26)
    History of contralateral breast cancer5 (13)
B. Characteristics of patients on prevention therapy at time of RPFNA
RPFNA sampling
Agent
Duration
Masood
Cell count
M3/M4 methylation
UnilateralTamoxifen2 wk14500+/+
Bilateral (L)Raloxifene2 y10<10−/−
Bilateral (R)1010−/−
UnilateralTamoxifen2 wk151,000+/−
UnilateralAromatase inhibitor1 yNANA−/−
UnilateralAromatase inhibitor1 yNANA−/−